Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neurodegenerative Diseases

Translational Research of the Nervous System

Vol. 16, No. 1-2, 2016

Issue release date: February 2016

Alzheimer's and Parkinson's Diseases: Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases

12th International Conference AD/PD, Nice, March 2015: Proceedings

See also ISBN 978-3-318-05682-2 for more details
Add all to MyReading List
 
1

Title Page / Table of Contents

Neurodegener Dis 2016;16:1-4 (DOI:10.1159/000442964)
Free Access
5

Preface

Neurodegener Dis 2016;16:5 (DOI:10.1159/000441937)
Free Access
Review
6

Defining the Genetic Architecture of Alzheimer's Disease: Where Next?

Sims R. · Williams J.
Neurodegener Dis 2016;16:6-11 (DOI:10.1159/000440841)
12

Genetic Disorders with Tau Pathology: A Review of the Literature and Report of Two Patients with Tauopathy and Positive Family Histories

Tacik P. · Sanchez-Contreras M. · Rademakers R. · Dickson D.W. · Wszolek Z.K.
Neurodegener Dis 2016;16:12-21 (DOI:10.1159/000440840)
22

Tau as the Converging Protein between Chronic Stress and Alzheimer's Disease Synaptic Pathology

Sotiropoulos I. · Sousa N.
Neurodegener Dis 2016;16:22-25 (DOI:10.1159/000440844)
26

Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies

Caso F. · Agosta F. · Filippi M.
Neurodegener Dis 2016;16:26-33 (DOI:10.1159/000441422)
34

Tau Immunotherapy

Sigurdsson E.M.
Neurodegener Dis 2016;16:34-38 (DOI:10.1159/000440842)
Original Paper
39

Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease

Beckelman B.C. · Zhou X. · Keene C.D. · Ma T.
Neurodegener Dis 2016;16:39-43 (DOI:10.1159/000438925)
44

Oxidized Docosahexaenoic Acid Species and Lipid Peroxidation Products Increase Amyloidogenic Amyloid Precursor Protein Processing

Grimm M.O.W. · Haupenthal V.J. · Mett J. · Stahlmann C.P. · Blümel T. · Mylonas N.T. · Endres K. · Grimm H.S. · Hartmann T.
Neurodegener Dis 2016;16:44-54 (DOI:10.1159/000440839)
55

Shared Molecular Mechanisms in Alzheimer's Disease and Amyotrophic Lateral Sclerosis: Neurofilament-Dependent Transport of sAPP, FUS, TDP-43 and SOD1, with Endoplasmic Reticulum-Like Tubules

Muresan V. · Ladescu Muresan Z.
Neurodegener Dis 2016;16:55-61 (DOI:10.1159/000439256)
62

Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome

Tramutola A. · Lanzillotta C. · Arena A. · Barone E. · Perluigi M. · Di Domenico F.
Neurodegener Dis 2016;16:62-68 (DOI:10.1159/000441419)
69

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Sierra-Rio A. · Balasa M. · Olives J. · Antonell A. · Iranzo A. · Castellví M. · Bosch B. · Grau-Rivera O. · Fernandez-Villullas G. · Rami L. · Lladó A. · Sánchez-Valle R. · Molinuevo J.L.
Neurodegener Dis 2016;16:69-76 (DOI:10.1159/000439258)
77

Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations

Orellana C. · Ferreira D. · Muehlboeck J.-S. · Mecocci P. · Vellas B. · Tsolaki M. · Kłoszewska I. · Soininen H. · Lovestone S. · Simmons A. · Wahlund L.-O. · Westman E. · for the AddNeuronMed consortium and for the Alzheimer's Disease Neuroimaging Initiative
Neurodegener Dis 2016;16:77-86 (DOI:10.1159/000442443)
87

Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum

Tosun D. · Schuff N. · Jagust W. · Weiner M.W. · for the Alzheimer''s Disease Neuroimaging Initiative
Neurodegener Dis 2016;16:87-94 (DOI:10.1159/000439257)
95

AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease

Fisher A. · Bezprozvanny I. · Wu L. · Ryskamp D.A. · Bar-Ner N. · Natan N. · Brandeis R. · Elkon H. · Nahum V. · Gershonov E. · LaFerla F.M. · Medeiros R.
Neurodegener Dis 2016;16:95-110 (DOI:10.1159/000440864)
111

Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?

Boccardi M. · Altomare D. · Ferrari C. · Festari C. · Antelmi L. · Pievani M. · Tarallo A. · Muscio C. · Guerra U.P. · Paghera B. · Padovani A. · Frisoni G.B. · and the INDIA-FBP Working Group
Neurodegener Dis 2016;16:111-117 (DOI:10.1159/000439255)
Brief Communication
118

PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies

Gomperts S.N. · Marquie M. · Locascio J.J. · Bayer S. · Johnson K.A. · Growdon J.H.
Neurodegener Dis 2016;16:118-124 (DOI:10.1159/000441421)
 
125

Author Index Vol. 16, No. 1-2, 2016

Neurodegener Dis 2016;16:125 (DOI:10.1159/000442965)
Free Access
126

Subject Index Vol. 16, No. 1-2, 2016

Neurodegener Dis 2016;16:126 (DOI:10.1159/000442966)
Free Access